Andrew M. Stein, Ph.D.
Affiliations: | 2007 | University of Michigan, Ann Arbor, Ann Arbor, MI |
Area:
Theoretical Condensed Matter PhysicsGoogle:
"Andrew Stein"Mean distance: 12.76
Parents
Sign in to add mentor| Leonard M. Sander | grad student | 2007 | University of Michigan | |
| (Mathematical models for glioma spheroid invasion in three-dimensional collagen-I gel.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Stein AM, Grupp SA, Levine JE, et al. (2017) CTL019 Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor (CAR) T Cells to Characterize the Impact of Tocilizumab on Expansion and to Identify Correlates of Cytokine Release Syndrome Severity Blood. 130: 2561-2561 |
| Goel V, Hurh E, Stein A, et al. (2016) Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology |
| Stein A, Bellmunt J, Escudier B, et al. (2013) Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial European Urology. 64: 994-1002 |
| Mietlowski WL, Stein AM, Bao W, et al. (2013) Prognostic value of waterfall plots with the addition of nontarget lesion data. Journal of Clinical Oncology. 31: 11082-11082 |
| Stein A, Wang W, Carter AA, et al. (2012) Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial. Bmc Cancer. 12: 311 |
| Mietlowski WL, Bao W, Wood PA, et al. (2012) Clinical importance of including new and nontarget lesion assessment of disease progression (PD) to predict overall survival (OS): Implications for randomized phase II study design. Journal of Clinical Oncology. 30: 2543-2543 |
| Stein AM, Carter A, Hollaender N, et al. (2011) Quantifying the effect of everolimus on both tumor growth and new metastases in metastatic renal cell carcinoma (RCC): A dynamic tumor model of the RECORD-1 phase III trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4602 |
| Reddy PL, Choppa P, Moradian MM, et al. (2011) Evaluation of MMR Concordance Based on Either International Scale (IS) or National Comprehensive Cancer Network (NCCN) Criteria Using Reconstructed “Virtual” CML Patient Profiles From the REVEAL BCR-ABL Methods Comparison Study, Blood. 118: 3542-3542 |
| Stein A, Wang W, Carter A, et al. (2011) 728 Dynamic Tumor Modelling Of The Record-1 Phase Ii Trial Of Everolimus Quantifies Relationship Between Dose And Tumor Growth In Metastatic Renal Cell Carcinoma European Urology Supplements. 10: 232 |
| Stein AM, Vader DA, Weitz DA, et al. (2011) The micromechanics of three-dimensional collagen-I gels Complexity. 16: 22-28 |